Hamamatsu Pharma Research specializes in non-clinical studies using non-human primates (NHPs).
This page showcases key features of the company’s non-clinical capability, examples of disease models, and case studies.
We hope it serves as a useful reference when you are selecting a non-clinical CRO.
EPHamamatsu Pharma Research specializes in non-clinical models with non-human primates such as crab-eating macaques—the experimental animals most closely related to humans.
By overcoming the limitations of conventional small animal models such as mice, the company has improved the accuracy of efficacy predictions in humans.
These studies are especially reliable in areas where human-like models are essential, including central nervous system (CNS) disorders and rare diseases.
In collaboration with Hamamatsu University School of Medicine, the company provides high-precision non-clinical studies utilizing the university’s proprietary “PIT method” and can offer co-development of new model or established disease models.
Their research covers a wide range of disease areas, including exudative and atrophic age-related macular degeneration, osteoarthritis of the knee, anti-tumor drug-induced neuropathic pain, cerebral infarction, and Parkinson’s disease.
Even when a candidate drug shows limited efficacy, the obtained data can provide valuable insights for the future research and development.
The company is equipped with teams of specialized researchers with advanced expertise in primate handling and testing.
They offer flexible work flow that allows for last-minute protocol modifications if necessary.
Hamamatsu Pharma Research is fully accredited by AAALAC International standard, ensuring the highest standards of animal welfare, ethics, and safety.
No information regarding partnered organizations was found on the official website.
Hamamatsu Pharma Research focuses on the development of experimental models for focal cerebral ischemia (acute and chronic) and Parkinson’s disease in small animals and monkeys.
For cerebral infarction, they offer middle cerebral artery (MCA) thrombus, permanent occlusion, transient occlusion, and embolization models, which enable quantification of infarct size and functional assessments.
For Parkinson’s disease, available models include the systemic MPTP administration model and the MPTP hemiparkinsonism model.
The company has developed various thrombosis models, including the PIT model (Photochemically Induced Thrombosis).
It can produce mural thrombi through balloon injury and perform quantitative evaluation using diagnostic ultrasound and MRI imaging technologies.
Hamamatsu Pharma Research focuses exclusively on non-clinical pharmacological testing and is actively engaged in research and development within this field.
| Address | 1-3-7 ShinMiyakoda, Hamana-ku, Hamamatsu City, Shizuoka, Japan |
|---|---|
| Tel | 053-543-4543 |
| Website | https://www.hpharma.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.